ALMS vs BMY
ALMS: Alumis is a clinical-stage biopharmaceutical company developing targeted TYK2 inhibitors to transform the treatment of immune-mediated and neurodegenerative diseases. BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally.
Side-by-side fundamentals
| Metric | ALMS | BMY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $6.97 | $59.58 | |
| Market cap | $3.1B | $121.7B | |
| P/E as of 2026-10-08 | n/a | 13.12 | |
| Net margin FY2025, SEC XBRL | -1011.7% | +14.6% | BMY higher |
| Operating margin FY2025, SEC XBRL | -1886.9% | n/a | |
| ROE FY2025, SEC XBRL | -80.8% | +38.2% | BMY higher |
| ROA FY2025, SEC XBRL | -59.1% | +7.8% | BMY higher |
| Debt / equity as of 2026-09-03 | 0.00 | 1.93 | ALMS lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +3.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +1.4% | |
| Dividend yield as of 2026-09-03 | n/a | +4.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 19 | BMY higher |
| Beta as of 2026-09-03 | 0.86 | 0.25 | |
| 1-year return as of 2026-10-08 close | +57.3% | +33.8% | ALMS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.